Honokiol and Magnolol As Renewable Resources for the Synthesis of Polymers Towards Biomedical and Engineering Applications
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Highly Water-Soluble Solid Dispersions of Honokiol: Preparation, Solubility, and Bioavailability Studies and Anti-Tumor Activity Evaluation
pharmaceutics Article Highly Water-Soluble Solid Dispersions of Honokiol: Preparation, Solubility, and Bioavailability Studies and Anti-Tumor Activity Evaluation Li Wang 1,2, Weiwei Wu 1,2, Lingling Wang 1,2, Lu Wang 1,2 and Xiuhua Zhao 1,2,* 1 College of Chemistry, Chemical Engineering and Resource Utilization, Northeast Forestry University, Harbin 150040, China; [email protected] (L.W.); [email protected] (W.W.); [email protected] (L.W.); [email protected] (L.W.) 2 Key Laboratory of Forest Plant Ecology, Northeast Forestry University, Ministry of Education, Harbin 150040, China * Correspondence: [email protected]; Tel.: +86-451-82191517; Fax: +86-451-82102082 Received: 18 September 2019; Accepted: 24 October 2019; Published: 1 November 2019 Abstract: Honokiol (HK), a well-tolerated natural product, has many multiple pharmacological activities. However, its poor water solubility and low bioavailability limit its clinical application and development. The aim of this research was to prepare the solid dispersion (SD) formulation of honokiol (HK) with poloxamer-188 (PLX) as the carrier, thereby improving its solubility and oral bioavailability. Firstly, by investigating the relationship between the addition amount of the PLX and the solubility of HK, and the effects of solid dispersions with different ratios of HK–PLX on the solubility of HK, we determined that the optimum ratio of PLX to HK was (1:4). Then, the HK–PLX (1:4) SD of HK was prepared using the solvent evaporation method. The morphology of the obtained HK–PLX (1:4) SD was different from that of free HK. The HK in the HK–PLX (1:4) SD existed in amorphous form and formed intermolecular hydrogen bonds with PLX. -
(12) Patent Application Publication (10) Pub. No.: US 2006/014 1075A1 Talbott (43) Pub
US 2006O141075A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/014 1075A1 Talbott (43) Pub. Date: Jun. 29, 2006 (54) METHODS AND COMPOSITIONS FOR Publication Classification WEIGHT MANAGEMENT AND MOOD ENHANCEMENT (51) Int. Cl. A6IR 36/82 (2006.01) A6IR 36/752 (2006.01) (76) Inventor: Shawn M. Talbott, Draper, UT (US) A6II 3/522 (2006.01) A6II 3/56 (2006.01) Correspondence Address: A6IR 33/26 (2006.01) MACPHERSON KWOK CHEN & HEID LLP A 6LX 36/575 (2006.01) 1762 TECHNOLOGY DRIVE, SUITE 226 (52) U.S. Cl. ......................... 424/729; 424/736: 424/774; SAN JOSE, CA 95110 (US) 424/769; 514/263.31; 514/171; 424/646 (21) Appl. No.: 11/360,312 (57) ABSTRACT The present invention provides nutritional Supplement com (22) Filed: Feb. 23, 2006 positions and processes for treatment using nutritional Supplements that assist in weight management. One aspect Related U.S. Application Data of the invention comprises the inclusion in a single Supple ment constituent(s) that assist in reduction of a subjects (62) Division of application No. 10/895.253, filed on Jul. cortisol level, thermogenic constituent(s), and constituent(s) 20, 2004. that assist in stabilizing blood Sugar levels. Patent Application Publication Jun. 29, 2006 Sheet 1 of 4 US 2006/01.41075A1 Global Mood State (Profile of Mood States) 160 -8.6% 150 140 130 120 o Mood, Pre 110 Effect of a stress/cortisol-controlling dietary supplement on Global Mood States following 12 weeks of supplementation. P = placebo. S = Supplement. * = P <0.05 compared to Pre. -
Herbal Insomnia Medications That Target Gabaergic Systems: a Review of the Psychopharmacological Evidence
Send Orders for Reprints to [email protected] Current Neuropharmacology, 2014, 12, 000-000 1 Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence Yuan Shia, Jing-Wen Donga, Jiang-He Zhaob, Li-Na Tanga and Jian-Jun Zhanga,* aState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China; bDepartment of Pharmacology, School of Marine, Shandong University, Weihai, P.R. China Abstract: Insomnia is a common sleep disorder which is prevalent in women and the elderly. Current insomnia drugs mainly target the -aminobutyric acid (GABA) receptor, melatonin receptor, histamine receptor, orexin, and serotonin receptor. GABAA receptor modulators are ordinarily used to manage insomnia, but they are known to affect sleep maintenance, including residual effects, tolerance, and dependence. In an effort to discover new drugs that relieve insomnia symptoms while avoiding side effects, numerous studies focusing on the neurotransmitter GABA and herbal medicines have been conducted. Traditional herbal medicines, such as Piper methysticum and the seed of Zizyphus jujuba Mill var. spinosa, have been widely reported to improve sleep and other mental disorders. These herbal medicines have been applied for many years in folk medicine, and extracts of these medicines have been used to study their pharmacological actions and mechanisms. Although effective and relatively safe, natural plant products have some side effects, such as hepatotoxicity and skin reactions effects of Piper methysticum. In addition, there are insufficient evidences to certify the safety of most traditional herbal medicine. In this review, we provide an overview of the current state of knowledge regarding a variety of natural plant products that are commonly used to treat insomnia to facilitate future studies. -
Review Article Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development
Hindawi Publishing Corporation Evidence-Based Complementary and Alternative Medicine Volume 2015, Article ID 238482, 26 pages http://dx.doi.org/10.1155/2015/238482 Review Article Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development Charu Sharma,1 Bassem Sadek,2 Sameer N. Goyal,3 Satyesh Sinha,4 Mohammad Amjad Kamal,5,6 and Shreesh Ojha2 1 Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box 17666, Al Ain, Abu Dhabi, UAE 2Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box 17666, Al Ain, Abu Dhabi, UAE 3DepartmentofPharmacology,R.C.PatelInstituteofPharmaceuticalEducation&Research,Shirpur,Mahrastra425405,India 4Department of Internal Medicine, College of Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA 5King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia 6Enzymoics, 7 Peterlee Place, Hebersham, NSW 2770, Australia Correspondence should be addressed to Shreesh Ojha; [email protected] Received 24 April 2015; Accepted 24 August 2015 Academic Editor: Ki-Wan Oh Copyright © 2015 Charu Sharma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The cannabinoid molecules are derived from Cannabis sativa plant which acts on the cannabinoid receptors types 1 and 2 (CB1 and CB2) which have been explored as potential therapeutic targets for drug discovery and development. Currently, there are 9 numerous cannabinoid based synthetic drugs used in clinical practice like the popular ones such as nabilone, dronabinol, and Δ - tetrahydrocannabinol mediates its action through CB1/CB2 receptors. -
NRDC: Generally Recognized As Secret
NRDC Report April 2014 Generally Recognized as Secret: Chemicals Added to Food in the United States Tom Neltner, J.D., Maricel Maffini, Ph.D. Natural Resources Defense Council In April 2014, the Natural Resources Defense Council (NRDC) released a report raising concerns about a loophole in the Food Additives Amendment of 1958 for substances designated by food manufacturers as “generally recognized as safe” (GRAS). The report identified 56 companies that appeared to market 275 chemicals for use in food based on undisclosed GRAS safety determinations. For each chemical we identified in this study, we did not find evidence that FDA had cleared them for use in food. The 1958 law exempted from the formal, extended FDA approval process common food ingredients like vinegar and vegetable oil whose use qualifies as GRAS. It may have appeared reasonable at the time, but that exemption has been stretched into a loophole that has swallowed the law. The exemption allows manufacturers to make safety determinations that the uses of their newest chemicals in food are safe without notifying the FDA. The agency’s attempts to limit these undisclosed GRAS determinations by asking industry to voluntarily inform the FDA about their chemicals are insufficient to ensure the safety of our food in today’s global marketplace with a complex food supply. Furthermore, no other developed country in the world has a system like GRAS to provide oversight of food ingredients. In Table 1 and 2 of the report, NRDC identified the 56 companies and the number of chemicals that each company appeared to market as GRAS without FDA clearance. -
Herbal Remedies and Their Possible Effect on the Gabaergic System and Sleep
nutrients Review Herbal Remedies and Their Possible Effect on the GABAergic System and Sleep Oliviero Bruni 1,* , Luigi Ferini-Strambi 2,3, Elena Giacomoni 4 and Paolo Pellegrino 4 1 Department of Developmental and Social Psychology, Sapienza University, 00185 Rome, Italy 2 Department of Neurology, Ospedale San Raffaele Turro, 20127 Milan, Italy; [email protected] 3 Sleep Disorders Center, Vita-Salute San Raffaele University, 20132 Milan, Italy 4 Department of Medical Affairs, Sanofi Consumer HealthCare, 20158 Milan, Italy; Elena.Giacomoni@sanofi.com (E.G.); Paolo.Pellegrino@sanofi.com (P.P.) * Correspondence: [email protected]; Tel.: +39-33-5607-8964; Fax: +39-06-3377-5941 Abstract: Sleep is an essential component of physical and emotional well-being, and lack, or dis- ruption, of sleep due to insomnia is a highly prevalent problem. The interest in complementary and alternative medicines for treating or preventing insomnia has increased recently. Centuries-old herbal treatments, popular for their safety and effectiveness, include valerian, passionflower, lemon balm, lavender, and Californian poppy. These herbal medicines have been shown to reduce sleep latency and increase subjective and objective measures of sleep quality. Research into their molecular components revealed that their sedative and sleep-promoting properties rely on interactions with various neurotransmitter systems in the brain. Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter that plays a major role in controlling different vigilance states. GABA receptors are the targets of many pharmacological treatments for insomnia, such as benzodiazepines. Here, we perform a systematic analysis of studies assessing the mechanisms of action of various herbal medicines on different subtypes of GABA receptors in the context of sleep control. -
Preparation of Submicron Particles for Theranostic Applications: Imaging
Preparation of submicron particles for theranostic applications : imaging and therapy Muhammad Iqbal To cite this version: Muhammad Iqbal. Preparation of submicron particles for theranostic applications : imaging and therapy. Other. Université Claude Bernard - Lyon I, 2015. English. NNT : 2015LYO10227. tel- 01290059 HAL Id: tel-01290059 https://tel.archives-ouvertes.fr/tel-01290059 Submitted on 17 Mar 2016 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. N°d’ordre: 227-2015 Année 2015 THESE Présentée devant L’UNIVERSITE CLAUDE BERNARD – Lyon 1 Pour l’obtention du Diplôme de DOCTORAT Spécialité Pharmacotechnie Par Muhammad IQBAL Soutenue publiquement le 13 Novembre 2015 “Préparation de particules submicroniques pour applications théranostiques: imagerie et thérapie” Jury : Salima Saidi Professeur Université d’Oran, Algeria Serge Stoll Professeur Université de Genève, Switzerland Stéphanie Briançon Professeur Université Claude Bernard Lyon 1, France Amane JADA CR1-HDR-CNRS Institut de Sciences Des Matériaux De Mulhouse Hatem Fessi Professeur Co-directeur de thèse (Université Lyon-1) Abdelhamid Elaissari DR-CNRS Directeur de thèse (LAGEP, Université Lyon-1) UNIVERSITE CLAUDE BERNARD - LYON 1 Président de l’Université M. François-Noël GILLY Vice-président du Conseil d’Administration M. -
Therapeutic Applications of Compounds in the Magnolia Family
Pharmacology & Therapeutics 130 (2011) 157–176 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate Editor: I. Kimura Therapeutic applications of compounds in the Magnolia family Young-Jung Lee a, Yoot Mo Lee a,b, Chong-Kil Lee a, Jae Kyung Jung a, Sang Bae Han a, Jin Tae Hong a,⁎ a College of Pharmacy and Medical Research Center, Chungbuk National University, 12 Gaesin-dong, Heungduk-gu, Cheongju, Chungbuk 361-763, Republic of Korea b Reviewer & Scientificofficer, Bioequivalence Evaluation Division, Drug Evaluation Department Pharmaceutical Safety Breau, Korea Food & Drug Administration, Republic of Korea article info abstract Keywords: The bark and/or seed cones of the Magnolia tree have been used in traditional herbal medicines in Korea, Magnolia China and Japan. Bioactive ingredients such as magnolol, honokiol, 4-O-methylhonokiol and obovatol have Magnolol received great attention, judging by the large number of investigators who have studied their Obovatol pharmacological effects for the treatment of various diseases. Recently, many investigators reported the Honokiol anti-cancer, anti-stress, anti-anxiety, anti-depressant, anti-oxidant, anti-inflammatory and hepatoprotective 4-O-methylhonokiol effects as well as toxicities and pharmacokinetics data, however, the mechanisms underlying these Cancer Nerve pharmacological activities are not clear. The aim of this study was to review a variety of experimental and Alzheimer disease clinical reports and, describe the effectiveness, toxicities and pharmacokinetics, and possible mechanisms of Cardiovascular disease Magnolia and/or its constituents. Inflammatory disease © 2011 Elsevier Inc. All rights reserved. Contents 1. Introduction .............................................. 157 2. Components of Magnolia ........................................ 159 3. Therapeutic applications in cancer ................................... -
Synthesis of Magnolol and Its Analogue Compounds Synthese Von Magnolol Und Analog-Verbindungen Synthèse De Magnolol Et Ses Composés Analogues
(19) TZZ ¥¥_Z_T (11) EP 2 539 310 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07C 37/055 (2006.01) C07C 37/62 (2006.01) 16.07.2014 Bulletin 2014/29 C07C 39/21 (2006.01) C07C 41/48 (2006.01) C07C 41/52 (2006.01) C07C 43/313 (2006.01) (2006.01) (2006.01) (21) Application number: 10705965.1 C07C 43/30 A61K 31/05 A61P 31/04 (2006.01) (22) Date of filing: 25.02.2010 (86) International application number: PCT/US2010/025378 (87) International publication number: WO 2011/106003 (01.09.2011 Gazette 2011/35) (54) SYNTHESIS OF MAGNOLOL AND ITS ANALOGUE COMPOUNDS SYNTHESE VON MAGNOLOL UND ANALOG-VERBINDUNGEN SYNTHÈSE DE MAGNOLOL ET SES COMPOSÉS ANALOGUES (84) Designated Contracting States: • SUBRAMANYAM, Ravi AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Belle Mead HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL NJ 08502 (US) PT RO SE SI SK SM TR (74) Representative: Jenkins, Peter David (43) Date of publication of application: Page White & Farrer 02.01.2013 Bulletin 2013/01 Bedford House John Street (73) Proprietors: London WC1N 2BF (GB) •Colgate-Palmolive Company New York, NY 10022 (US) (56) References cited: • Indian Institute Of Chemical Technology US-A1- 2006 140 885 Andhra Pradesh (IN) • J. RUNEBERG: "Phenol Dehydrogenations" (72) Inventors: ACTA CHEMICA SCANDINAVICA, vol. 12, 1958, • REDDY, Basi, V., Subba pages 188-192, XP002575197 cited in the Nacharam (IN) application • YADAV, Jhillu, S. -
Honokiol Inhibits Lung Tumorigenesis Through Inhibition of Mitochondrial Function
Published OnlineFirst September 22, 2014; DOI: 10.1158/1940-6207.CAPR-14-0091 Cancer Prevention Research Article Research Honokiol Inhibits Lung Tumorigenesis through Inhibition of Mitochondrial Function Jing Pan1, Qi Zhang1, Qian Liu1, Steven M. Komas2, Balaraman Kalyanaraman2, Ronald A. Lubet3, Yian Wang1, and Ming You1 Abstract Honokiol is an important bioactive compound found in the bark of Magnolia tree. It is a non- adipogenic PPARg agonist and capable of inhibiting the growth of a variety of tumor types both in vitro and in xenograft models. However, to fully appreciate the potential chemopreventive activity of honokiol, a less artificial model system is required. To that end, this study examined the chemopreven- tive efficacy of honokiol in an initiation model of lung squamous cell carcinoma (SCC). This model system uses the carcinogen N-nitroso-trischloroethylurea (NTCU), which is applied topically, reliably triggering the development of SCC within 24 to 26 weeks. Administration of honokiol significantly reduced the percentage of bronchial that exhibit abnormal lung SCC histology from 24.4% bronchial in control to 11.0% bronchial in honokiol-treated group (P ¼ 0.01) while protecting normal bronchial histology (present in 20.5% of bronchial in control group and 38.5% of bronchial in honokiol-treated group. P ¼ 0.004). P63 staining at the SCC site confirmed the lung SCCs phenotype. In vitro studies revealed that honokiol inhibited lung SCC cells proliferation, arrested cells at the G1–S cell-cycle checkpoint, while also leading to increased apoptosis. Our study showed that interfering with mitochondrial respiration is a novel mechanism by which honokiol changed redox status in the mitochondria, triggered apoptosis, and finally leads to the inhibition of lung SCC. -
Nutrition Biofiles7
2007 Volume 2 Number 2 FOR LIFE SCIENCE RESEARCH DIETARY ANTIOXIDANTS OMEGA-3 FATTY ACIDS AND HEART DISEASE THE BIOACTIVE NUTRIENT EXPLORER METABOLITE LIBRARIES Examples of fruits and vegetables that contain antioxidants such as kaempferol, lycopene, and resveratrol. Nutrition Research sigma-aldrich.com Life Science Pathways Animated ATP Synthase & Glycolysis! The evolutionary pathway of life science research has brought today’s researchers full circle to a destination we now call metabolomics. n 1947, Sigma produced the first commercially The Enzyme Explorer’s Metabolic Pathways The Enzyme Explorer I available ATP. Since then, Sigma-Aldrich has Resource Center provides the online tools you need Assay Library consistently expanded its product portfolio to to explore the metabolome today. The largest collection of enzymatic maintain the most comprehensive line of organic • Metabolic Pathway Chart with 500 Hyperlinks assay procedures available online. More than 600 step-by-step metabolites, enzymes, and bio-analytical tools in to Product Listings, and Technical Data procedures for: the world. • Direct Access to 35 Nicholson Metabolic Mini-maps To strengthen our commitment to metabolic METABOLIC ENZYMES • Animated ATP Synthase Mechanism METABOLITE QUANTITATION education and research, Sigma-Aldrich is proud DIAGNOSTIC ENZYMES to announce the formation of a collaboration • Animated Glycolysis Pathway ANALYTICAL ENZYMES with the IUBMB to produce, animate, and • Isotopically Labeled Metabolites PROTEASES PROTEASE INHIBITORS publish the Nicholson Metabolic Pathway Charts. • Metabolite Libraries CELL SIGNALING ENZYMES PROTEIN QUANTITATION Visit the Assay Library at: sigma-aldrich.com/enzymeexplorer Visit us online today at: sigma-aldrich.com/metpath LEADERSHIP IN LIFE SCIENCE, HIGH TECHNOLOGY AND SERVICE sigma-aldrich.com SIGMA-ALDRICH CORPORATION • BOX 14508 • ST. -
4-O-Methylhonokiol Protects Hacat Cells from TGF-Β1-Induced Cell Cycle Arrest by Regulating Canonical and Non-Canonical Pathways of TGF-Β Signaling
Original Article Biomol Ther 25(4), 417-426 (2017) 4-O-Methylhonokiol Protects HaCaT Cells from TGF-β1-Induced Cell Cycle Arrest by Regulating Canonical and Non-Canonical Pathways of TGF-β Signaling Sang-Cheol Kim1,3 Jung-Il Kang1, Jin-Won Hyun1, Ji-Hoon Kang1, Young-Sang Koh1, Young-Heui Kim2, Ki-Ho Kim2, Ji-Hee Ko1, Eun-Sook Yoo1 and Hee-Kyoung Kang1,* 1Department of Medicine, Jeju National University School of Medicine, Jeju 63243, 2R&D Center, Bioland Ltd., Cheonan 31257, 3Freshwater Bioresources Utilization Division, Nakdonggang National Institute of Biological Resourecs, Sangju 37242, Republic of Korea Abstract 4-O-methylhonokiol, a neolignan compound from Magnolia Officinalis, has been reported to have various biological activities including hair growth promoting effect. However, although transforming growth factor-β (TGF-β) signal pathway has an essen- tial role in the regression induction of hair growth, the effect of 4-O-methylhonokiol on the TGF-β signal pathway has not yet been elucidated. We thus examined the effect of 4-O-methylhonokiol on TGF-β-induced canonical and noncanonical pathways in HaCaT human keratinocytes. When HaCaT cells were pretreated with 4-O-methylhonokiol, TGF-β1-induced G1/G0 phase arrest and TGF-β1-induced p21 expression were decreased. Moreover, 4-O-methylhonokiol inhibited nuclear translocation of Smad2/3, Smad4 and Sp1 in TGF-β1-induced canonical pathway. We observed that ERK phosphorylation by TGF-β1 was significantly at- tenuated by treatment with 4-O-methylhonokiol. 4-O-methylhonokiol inhibited TGF-β1-induced reactive oxygen species (ROS) production and reduced the increase of NADPH oxidase 4 (NOX4) mRNA level in TGF-β1-induced noncanonical pathway.